Hepatology training in the UK

Abstract

to be obtained before widespread replacement of OPV with IPV. We therefore strongly urge SAGE to advocate for randomised trials to be done-to assess the relative eff ects of OPV and IPV on all-cause mortalitybefore any decision on phasing out OPV is made. The results would inform whether such a replacement to reduce vaccine-associated paralytic poliomyelitis would increase all-cause mortality, and whether a combined OPV and IPV schedule might decrease vaccine-associated paralytic poliomyelitis without increasing mortality.